Literature DB >> 31559120

Genomic characterization for familial cases with urothelial carcinoma.

Tetsuya Shindo1, Megumi Hirobe1,2, Yasushi Adachi3, Yasushi Sasaki4, Takashi Tokino4, Naoya Masumori1.   

Abstract

In this report, we present familial cases of urothelial carcinoma. To investigate the possibility of hereditary urothelial cancer, we performed semiconductor-based next-generation DNA sequencing. A woman in her 80s who had bladder and left ureteral cancer was hospitalized in Sapporo Shirakaba-dai Hospital due to consciousness disturbance. Radiographic evaluation revealed multiple liver metastases and she died 38 days later. Needle necropsy was done for a left ureteral tumor that continued to her bladder tumor and for liver metastases. At the same time, her son in his 60s, who also had muscle-invasive bladder cancer, was admitted to Sapporo Medical University Hospital and underwent neoadjuvant chemotherapy followed by laparoscopic radical cystectomy. DNA was isolated from both cancers and normal controls in each case and analyzed by massive parallel sequencing of 409 cancer-related genes using a targeted, multiplex PCR approach followed by semiconductor sequencing. Somatic mutations of KMT2C and KMT2D were detected in the mother's tumor. Copy number gains of FGFR1, IkBKB, NFkB2, FGFR2, and FLT3 and copy number losses of IGF2R and TP53 were also found in her cancer. In her son's tumor, somatic mutations of FGFR3 and EP300 were identified. Copy number gains of IkBKE/MAPK1/PARP1, EGFR, BRAF, IRS2, MAPK2K1, IGF1R, and ERBB2 and copy number loss of TP53 were also found in his cancer. There were no germline gene mutations related to familial urothelial carcinoma. Although somatic mutation of TP53 was a common feature, these cases with urothelial carcinoma might not be the result of a heredity syndrome.

Entities:  

Keywords:  Familial cancer; Next-generation sequencing; Urothelial cancer

Year:  2019        PMID: 31559120      PMCID: PMC6744538          DOI: 10.1007/s13691-019-00381-7

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  18 in total

Review 1.  Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome.

Authors:  P Barrow; M Khan; F Lalloo; D G Evans; J Hill
Journal:  Br J Surg       Date:  2013-12       Impact factor: 6.939

2.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.

Authors:  Aung Ko Win; Joanne P Young; Noralane M Lindor; Katherine M Tucker; Dennis J Ahnen; Graeme P Young; Daniel D Buchanan; Mark Clendenning; Graham G Giles; Ingrid Winship; Finlay A Macrae; Jack Goldblatt; Melissa C Southey; Julie Arnold; Stephen N Thibodeau; Shanaka R Gunawardena; Bharati Bapat; John A Baron; Graham Casey; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; John L Hopper; Mark A Jenkins
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

3.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

4.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

5.  FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.

Authors:  Ji-Youn Sung; Jong-Mu Sun; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi; So Young Kang; Yoon-La Choi; Ghee Young Kwon
Journal:  Urol Oncol       Date:  2014-01       Impact factor: 3.498

6.  Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.

Authors:  Sean C Skeldon; Kara Semotiuk; Melyssa Aronson; Spring Holter; Steven Gallinger; Aaron Pollett; Cynthia Kuk; Bas van Rhijn; Peter Bostrom; Zane Cohen; Neil E Fleshner; Michael A Jewett; Sally Hanna; Shahrokh F Shariat; Theodorus H Van Der Kwast; Andrew Evans; Jim Catto; Bharati Bapat; Alexandre R Zlotta
Journal:  Eur Urol       Date:  2012-08-02       Impact factor: 20.096

7.  Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours.

Authors:  Clémence Hollande; Pierre Colin; Thibault de La Motte Rouge; François Audenet; David R Yates; Véronique Phé; Adil Ouzzane; Stéphane Droupy; Alain Ruffion; Alexandre de La Taille; Laurent Guy; Olivier Cussenot; François Rozet; Evanguelos Xylinas; Marc Zerbib; Jean-Philippe Spano; David Khayat; Marc-Olivier Bitker; Morgan Rouprêt
Journal:  BJU Int       Date:  2013-08-13       Impact factor: 5.588

8.  HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome.

Authors:  Willemien Beukers; Aleksander Hercegovac; Ellen C Zwarthoff
Journal:  Eur J Hum Genet       Date:  2013-10-30       Impact factor: 4.246

Review 9.  Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum.

Authors:  Morgan Rouprêt; David R Yates; Eva Comperat; Olivier Cussenot
Journal:  Eur Urol       Date:  2008-08-12       Impact factor: 20.096

10.  Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.

Authors:  R S van der Post; L A Kiemeney; M J L Ligtenberg; J A Witjes; C A Hulsbergen-van de Kaa; D Bodmer; L Schaap; C M Kets; J H J M van Krieken; N Hoogerbrugge
Journal:  J Med Genet       Date:  2010-07       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.